nodes	percent_of_prediction	percent_of_DWPC	metapath
Hydrocodone—CYP2D6—Efavirenz—acquired immunodeficiency syndrome	0.0562	0.0809	CbGbCtD
Hydrocodone—CYP2D6—Nevirapine—acquired immunodeficiency syndrome	0.0529	0.0761	CbGbCtD
Hydrocodone—CYP2D6—Lopinavir—acquired immunodeficiency syndrome	0.0529	0.0761	CbGbCtD
Hydrocodone—CYP2D6—Amprenavir—acquired immunodeficiency syndrome	0.0478	0.0688	CbGbCtD
Hydrocodone—CYP2D6—Delavirdine—acquired immunodeficiency syndrome	0.0478	0.0688	CbGbCtD
Hydrocodone—CYP2D6—Indinavir—acquired immunodeficiency syndrome	0.0413	0.0594	CbGbCtD
Hydrocodone—CYP2D6—Nelfinavir—acquired immunodeficiency syndrome	0.0401	0.0576	CbGbCtD
Hydrocodone—CYP2D6—Saquinavir—acquired immunodeficiency syndrome	0.0362	0.0521	CbGbCtD
Hydrocodone—CYP2D6—Ritonavir—acquired immunodeficiency syndrome	0.0362	0.0521	CbGbCtD
Hydrocodone—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0358	0.0514	CbGbCtD
Hydrocodone—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0336	0.0484	CbGbCtD
Hydrocodone—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0336	0.0484	CbGbCtD
Hydrocodone—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.0304	0.0437	CbGbCtD
Hydrocodone—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.0304	0.0437	CbGbCtD
Hydrocodone—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0262	0.0378	CbGbCtD
Hydrocodone—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0255	0.0367	CbGbCtD
Hydrocodone—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.023	0.0331	CbGbCtD
Hydrocodone—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.023	0.0331	CbGbCtD
Hydrocodone—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0221	0.0318	CbGbCtD
Hydrocodone—OPRM1—nerve—acquired immunodeficiency syndrome	0.00236	0.185	CbGeAlD
Hydrocodone—OPRD1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00133	0.0289	CbGpPWpGaD
Hydrocodone—OPRK1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.00117	0.0253	CbGpPWpGaD
Hydrocodone—OPRD1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.00103	0.0224	CbGpPWpGaD
Hydrocodone—OPRM1—Peptide GPCRs—ACKR1—acquired immunodeficiency syndrome	0.000985	0.0214	CbGpPWpGaD
Hydrocodone—OPRK1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000905	0.0196	CbGpPWpGaD
Hydrocodone—OPRD1—nervous system—acquired immunodeficiency syndrome	0.000779	0.0609	CbGeAlD
Hydrocodone—OPRM1—Peptide ligand-binding receptors—CCL3L1—acquired immunodeficiency syndrome	0.000765	0.0166	CbGpPWpGaD
Hydrocodone—OPRD1—central nervous system—acquired immunodeficiency syndrome	0.00075	0.0586	CbGeAlD
Hydrocodone—OPRK1—nervous system—acquired immunodeficiency syndrome	0.000747	0.0584	CbGeAlD
Hydrocodone—OPRD1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000743	0.0161	CbGpPWpGaD
Hydrocodone—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.000728	0.0569	CbGeAlD
Hydrocodone—OPRK1—central nervous system—acquired immunodeficiency syndrome	0.000719	0.0562	CbGeAlD
Hydrocodone—CYP2D6—blood plasma—acquired immunodeficiency syndrome	0.000716	0.056	CbGeAlD
Hydrocodone—OPRD1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000698	0.0152	CbGpPWpGaD
Hydrocodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000692	0.015	CbGpPWpGaD
Hydrocodone—OPRM1—blood—acquired immunodeficiency syndrome	0.000654	0.0512	CbGeAlD
Hydrocodone—OPRK1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.000651	0.0141	CbGpPWpGaD
Hydrocodone—OPRM1—spinal cord—acquired immunodeficiency syndrome	0.000631	0.0493	CbGeAlD
Hydrocodone—OPRD1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000625	0.0136	CbGpPWpGaD
Hydrocodone—OPRK1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000612	0.0133	CbGpPWpGaD
Hydrocodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000607	0.0132	CbGpPWpGaD
Hydrocodone—OPRD1—brain—acquired immunodeficiency syndrome	0.000595	0.0465	CbGeAlD
Hydrocodone—OPRK1—brain—acquired immunodeficiency syndrome	0.000571	0.0446	CbGeAlD
Hydrocodone—OPRD1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000565	0.0123	CbGpPWpGaD
Hydrocodone—OPRM1—Peptide GPCRs—CCR2—acquired immunodeficiency syndrome	0.00055	0.0119	CbGpPWpGaD
Hydrocodone—OPRK1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000548	0.0119	CbGpPWpGaD
Hydrocodone—OPRM1—nervous system—acquired immunodeficiency syndrome	0.000531	0.0415	CbGeAlD
Hydrocodone—OPRD1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000527	0.0114	CbGpPWpGaD
Hydrocodone—OPRM1—Peptide GPCRs—CXCR4—acquired immunodeficiency syndrome	0.000517	0.0112	CbGpPWpGaD
Hydrocodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3L1—acquired immunodeficiency syndrome	0.000513	0.0111	CbGpPWpGaD
Hydrocodone—OPRM1—central nervous system—acquired immunodeficiency syndrome	0.000512	0.04	CbGeAlD
Hydrocodone—OPRK1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000496	0.0108	CbGpPWpGaD
Hydrocodone—OPRD1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000478	0.0104	CbGpPWpGaD
Hydrocodone—OPRM1—Peptide ligand-binding receptors—ACKR1—acquired immunodeficiency syndrome	0.000463	0.0101	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000462	0.01	CbGpPWpGaD
Hydrocodone—OPRM1—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000452	0.00981	CbGpPWpGaD
Hydrocodone—OPRM1—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000452	0.00981	CbGpPWpGaD
Hydrocodone—OPRM1—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000439	0.00954	CbGpPWpGaD
Hydrocodone—OPRK1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.00042	0.00911	CbGpPWpGaD
Hydrocodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000419	0.0091	CbGpPWpGaD
Hydrocodone—OPRM1—Peptide ligand-binding receptors—CCL4—acquired immunodeficiency syndrome	0.000419	0.0091	CbGpPWpGaD
Hydrocodone—OPRM1—brain—acquired immunodeficiency syndrome	0.000406	0.0317	CbGeAlD
Hydrocodone—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000405	0.00165	CcSEcCtD
Hydrocodone—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000405	0.00165	CcSEcCtD
Hydrocodone—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000404	0.00164	CcSEcCtD
Hydrocodone—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000404	0.00164	CcSEcCtD
Hydrocodone—Thrombocytopenia—Indinavir—acquired immunodeficiency syndrome	0.000404	0.00164	CcSEcCtD
Hydrocodone—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000404	0.00164	CcSEcCtD
Hydrocodone—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000404	0.00164	CcSEcCtD
Hydrocodone—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000404	0.00164	CcSEcCtD
Hydrocodone—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000402	0.00163	CcSEcCtD
Hydrocodone—Insomnia—Zidovudine—acquired immunodeficiency syndrome	0.000401	0.00163	CcSEcCtD
Hydrocodone—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.000401	0.00163	CcSEcCtD
Hydrocodone—Hyperhidrosis—Indinavir—acquired immunodeficiency syndrome	0.000399	0.00162	CcSEcCtD
Hydrocodone—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000399	0.00162	CcSEcCtD
Hydrocodone—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.000399	0.00162	CcSEcCtD
Hydrocodone—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.000398	0.00162	CcSEcCtD
Hydrocodone—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000398	0.00162	CcSEcCtD
Hydrocodone—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000398	0.00162	CcSEcCtD
Hydrocodone—Tremor—Ritonavir—acquired immunodeficiency syndrome	0.000396	0.00161	CcSEcCtD
Hydrocodone—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000396	0.00161	CcSEcCtD
Hydrocodone—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.000395	0.0016	CcSEcCtD
Hydrocodone—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000394	0.0016	CcSEcCtD
Hydrocodone—Muscle spasms—Saquinavir—acquired immunodeficiency syndrome	0.000391	0.00159	CcSEcCtD
Hydrocodone—OPRM1—GPCR ligand binding—CCL3L1—acquired immunodeficiency syndrome	0.000391	0.00848	CbGpPWpGaD
Hydrocodone—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.00039	0.00158	CcSEcCtD
Hydrocodone—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000389	0.00158	CcSEcCtD
Hydrocodone—Myalgia—Delavirdine—acquired immunodeficiency syndrome	0.000389	0.00158	CcSEcCtD
Hydrocodone—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000388	0.00158	CcSEcCtD
Hydrocodone—Anxiety—Delavirdine—acquired immunodeficiency syndrome	0.000388	0.00158	CcSEcCtD
Hydrocodone—OPRD1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000386	0.00839	CbGpPWpGaD
Hydrocodone—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000383	0.00156	CcSEcCtD
Hydrocodone—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000383	0.00156	CcSEcCtD
Hydrocodone—Fatigue—Zidovudine—acquired immunodeficiency syndrome	0.000383	0.00156	CcSEcCtD
Hydrocodone—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000382	0.00155	CcSEcCtD
Hydrocodone—Thrombocytopenia—Efavirenz—acquired immunodeficiency syndrome	0.000382	0.00155	CcSEcCtD
Hydrocodone—Tremor—Saquinavir—acquired immunodeficiency syndrome	0.000381	0.00155	CcSEcCtD
Hydrocodone—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.000381	0.00155	CcSEcCtD
Hydrocodone—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.00038	0.00154	CcSEcCtD
Hydrocodone—Asthenia—Nevirapine—acquired immunodeficiency syndrome	0.000379	0.00154	CcSEcCtD
Hydrocodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000379	0.00823	CbGpPWpGaD
Hydrocodone—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000379	0.00154	CcSEcCtD
Hydrocodone—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000377	0.00153	CcSEcCtD
Hydrocodone—Hyperhidrosis—Efavirenz—acquired immunodeficiency syndrome	0.000377	0.00153	CcSEcCtD
Hydrocodone—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000376	0.00153	CcSEcCtD
Hydrocodone—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000376	0.00153	CcSEcCtD
Hydrocodone—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000376	0.00153	CcSEcCtD
Hydrocodone—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000374	0.00152	CcSEcCtD
Hydrocodone—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000374	0.00152	CcSEcCtD
Hydrocodone—Insomnia—Indinavir—acquired immunodeficiency syndrome	0.000373	0.00152	CcSEcCtD
Hydrocodone—Muscle spasms—Lamivudine—acquired immunodeficiency syndrome	0.000373	0.00152	CcSEcCtD
Hydrocodone—Rash—Didanosine—acquired immunodeficiency syndrome	0.000371	0.00151	CcSEcCtD
Hydrocodone—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000371	0.00151	CcSEcCtD
Hydrocodone—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000371	0.00151	CcSEcCtD
Hydrocodone—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000371	0.00151	CcSEcCtD
Hydrocodone—Cough—Ritonavir—acquired immunodeficiency syndrome	0.000369	0.0015	CcSEcCtD
Hydrocodone—Headache—Didanosine—acquired immunodeficiency syndrome	0.000369	0.0015	CcSEcCtD
Hydrocodone—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000368	0.0015	CcSEcCtD
Hydrocodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000368	0.00798	CbGpPWpGaD
Hydrocodone—Asthenia—Nelfinavir—acquired immunodeficiency syndrome	0.000368	0.00149	CcSEcCtD
Hydrocodone—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.000367	0.00149	CcSEcCtD
Hydrocodone—Asthenia—Stavudine—acquired immunodeficiency syndrome	0.000366	0.00149	CcSEcCtD
Hydrocodone—Convulsion—Ritonavir—acquired immunodeficiency syndrome	0.000366	0.00149	CcSEcCtD
Hydrocodone—Thrombocytopenia—Delavirdine—acquired immunodeficiency syndrome	0.000365	0.00149	CcSEcCtD
Hydrocodone—Tremor—Lamivudine—acquired immunodeficiency syndrome	0.000364	0.00148	CcSEcCtD
Hydrocodone—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000363	0.00148	CcSEcCtD
Hydrocodone—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000362	0.00147	CcSEcCtD
Hydrocodone—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000362	0.00147	CcSEcCtD
Hydrocodone—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000361	0.00147	CcSEcCtD
Hydrocodone—Asthenia—Abacavir—acquired immunodeficiency syndrome	0.000361	0.00147	CcSEcCtD
Hydrocodone—Hyperhidrosis—Delavirdine—acquired immunodeficiency syndrome	0.000361	0.00147	CcSEcCtD
Hydrocodone—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.00036	0.00146	CcSEcCtD
Hydrocodone—Myalgia—Ritonavir—acquired immunodeficiency syndrome	0.00036	0.00146	CcSEcCtD
Hydrocodone—Anxiety—Ritonavir—acquired immunodeficiency syndrome	0.000359	0.00146	CcSEcCtD
Hydrocodone—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.000358	0.00145	CcSEcCtD
Hydrocodone—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000356	0.00145	CcSEcCtD
Hydrocodone—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000356	0.00145	CcSEcCtD
Hydrocodone—Fatigue—Indinavir—acquired immunodeficiency syndrome	0.000356	0.00145	CcSEcCtD
Hydrocodone—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000355	0.00144	CcSEcCtD
Hydrocodone—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000355	0.00144	CcSEcCtD
Hydrocodone—OPRM1—Peptide GPCRs—CCR5—acquired immunodeficiency syndrome	0.000355	0.0077	CbGpPWpGaD
Hydrocodone—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000353	0.00143	CcSEcCtD
Hydrocodone—Insomnia—Efavirenz—acquired immunodeficiency syndrome	0.000353	0.00143	CcSEcCtD
Hydrocodone—Convulsion—Saquinavir—acquired immunodeficiency syndrome	0.000353	0.00143	CcSEcCtD
Hydrocodone—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.000352	0.00143	CcSEcCtD
Hydrocodone—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000351	0.00143	CcSEcCtD
Hydrocodone—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000351	0.00143	CcSEcCtD
Hydrocodone—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.00035	0.00142	CcSEcCtD
Hydrocodone—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000349	0.00142	CcSEcCtD
Hydrocodone—OPRD1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000349	0.00758	CbGpPWpGaD
Hydrocodone—Hypotension—Delavirdine—acquired immunodeficiency syndrome	0.000349	0.00142	CcSEcCtD
Hydrocodone—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000348	0.00141	CcSEcCtD
Hydrocodone—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.000347	0.00141	CcSEcCtD
Hydrocodone—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000346	0.00141	CcSEcCtD
Hydrocodone—Myalgia—Saquinavir—acquired immunodeficiency syndrome	0.000346	0.00141	CcSEcCtD
Hydrocodone—Anxiety—Saquinavir—acquired immunodeficiency syndrome	0.000345	0.0014	CcSEcCtD
Hydrocodone—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000344	0.0014	CcSEcCtD
Hydrocodone—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.00034	0.00138	CcSEcCtD
Hydrocodone—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.000339	0.00138	CcSEcCtD
Hydrocodone—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000339	0.00138	CcSEcCtD
Hydrocodone—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	0.000339	0.00138	CcSEcCtD
Hydrocodone—OPRK1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000339	0.00735	CbGpPWpGaD
Hydrocodone—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000338	0.00138	CcSEcCtD
Hydrocodone—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	0.000338	0.00137	CcSEcCtD
Hydrocodone—Dizziness—Stavudine—acquired immunodeficiency syndrome	0.000338	0.00137	CcSEcCtD
Hydrocodone—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000338	0.00137	CcSEcCtD
Hydrocodone—Insomnia—Delavirdine—acquired immunodeficiency syndrome	0.000338	0.00137	CcSEcCtD
Hydrocodone—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.000337	0.00137	CcSEcCtD
Hydrocodone—Convulsion—Lamivudine—acquired immunodeficiency syndrome	0.000336	0.00137	CcSEcCtD
Hydrocodone—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.000336	0.00137	CcSEcCtD
Hydrocodone—Fatigue—Efavirenz—acquired immunodeficiency syndrome	0.000336	0.00137	CcSEcCtD
Hydrocodone—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000335	0.00136	CcSEcCtD
Hydrocodone—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000335	0.00136	CcSEcCtD
Hydrocodone—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	0.000334	0.00136	CcSEcCtD
Hydrocodone—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000334	0.00136	CcSEcCtD
Hydrocodone—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000334	0.00136	CcSEcCtD
Hydrocodone—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000333	0.00135	CcSEcCtD
Hydrocodone—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000333	0.00135	CcSEcCtD
Hydrocodone—Dizziness—Abacavir—acquired immunodeficiency syndrome	0.000333	0.00135	CcSEcCtD
Hydrocodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000332	0.00722	CbGpPWpGaD
Hydrocodone—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.000332	0.00135	CcSEcCtD
Hydrocodone—OPRM1—TCR Signaling Pathway—CD8A—acquired immunodeficiency syndrome	0.000331	0.0072	CbGpPWpGaD
Hydrocodone—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000331	0.00135	CcSEcCtD
Hydrocodone—Myalgia—Lamivudine—acquired immunodeficiency syndrome	0.000331	0.00134	CcSEcCtD
Hydrocodone—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000331	0.00134	CcSEcCtD
Hydrocodone—Anxiety—Lamivudine—acquired immunodeficiency syndrome	0.000329	0.00134	CcSEcCtD
Hydrocodone—OPRD1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000328	0.00713	CbGpPWpGaD
Hydrocodone—OPRD1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000328	0.00713	CbGpPWpGaD
Hydrocodone—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000328	0.00133	CcSEcCtD
Hydrocodone—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000326	0.00133	CcSEcCtD
Hydrocodone—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000326	0.00133	CcSEcCtD
Hydrocodone—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000326	0.00132	CcSEcCtD
Hydrocodone—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.000326	0.00132	CcSEcCtD
Hydrocodone—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	0.000325	0.00132	CcSEcCtD
Hydrocodone—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000325	0.00132	CcSEcCtD
Hydrocodone—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.000323	0.00131	CcSEcCtD
Hydrocodone—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000323	0.00131	CcSEcCtD
Hydrocodone—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000323	0.00131	CcSEcCtD
Hydrocodone—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000323	0.00131	CcSEcCtD
Hydrocodone—Hypotension—Ritonavir—acquired immunodeficiency syndrome	0.000322	0.00131	CcSEcCtD
Hydrocodone—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000322	0.00131	CcSEcCtD
Hydrocodone—Rash—Stavudine—acquired immunodeficiency syndrome	0.000322	0.00131	CcSEcCtD
Hydrocodone—Fatigue—Delavirdine—acquired immunodeficiency syndrome	0.000322	0.00131	CcSEcCtD
Hydrocodone—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000322	0.00131	CcSEcCtD
Hydrocodone—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	0.000321	0.00131	CcSEcCtD
Hydrocodone—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000321	0.0013	CcSEcCtD
Hydrocodone—Headache—Stavudine—acquired immunodeficiency syndrome	0.00032	0.0013	CcSEcCtD
Hydrocodone—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00032	0.0013	CcSEcCtD
Hydrocodone—OPRD1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000319	0.00693	CbGpPWpGaD
Hydrocodone—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000319	0.0013	CcSEcCtD
Hydrocodone—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000319	0.0013	CcSEcCtD
Hydrocodone—Asthenia—Zidovudine—acquired immunodeficiency syndrome	0.000318	0.00129	CcSEcCtD
Hydrocodone—Rash—Abacavir—acquired immunodeficiency syndrome	0.000317	0.00129	CcSEcCtD
Hydrocodone—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000317	0.00129	CcSEcCtD
Hydrocodone—Headache—Abacavir—acquired immunodeficiency syndrome	0.000315	0.00128	CcSEcCtD
Hydrocodone—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.000314	0.00128	CcSEcCtD
Hydrocodone—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.000314	0.00128	CcSEcCtD
Hydrocodone—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.000314	0.00128	CcSEcCtD
Hydrocodone—Insomnia—Ritonavir—acquired immunodeficiency syndrome	0.000312	0.00127	CcSEcCtD
Hydrocodone—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000311	0.00126	CcSEcCtD
Hydrocodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—ACKR1—acquired immunodeficiency syndrome	0.000311	0.00675	CbGpPWpGaD
Hydrocodone—Hypotension—Saquinavir—acquired immunodeficiency syndrome	0.00031	0.00126	CcSEcCtD
Hydrocodone—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	0.00031	0.00126	CcSEcCtD
Hydrocodone—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.00031	0.00126	CcSEcCtD
Hydrocodone—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000308	0.00125	CcSEcCtD
Hydrocodone—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000308	0.00125	CcSEcCtD
Hydrocodone—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000308	0.00125	CcSEcCtD
Hydrocodone—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000308	0.00125	CcSEcCtD
Hydrocodone—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.000307	0.00125	CcSEcCtD
Hydrocodone—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	0.000306	0.00124	CcSEcCtD
Hydrocodone—OPRK1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000306	0.00665	CbGpPWpGaD
Hydrocodone—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000305	0.00124	CcSEcCtD
Hydrocodone—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000304	0.00124	CcSEcCtD
Hydrocodone—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.000304	0.00124	CcSEcCtD
Hydrocodone—Nausea—Stavudine—acquired immunodeficiency syndrome	0.000303	0.00123	CcSEcCtD
Hydrocodone—OPRM1—TCR Signaling Pathway—CCR5—acquired immunodeficiency syndrome	0.000303	0.00658	CbGpPWpGaD
Hydrocodone—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000303	0.00123	CcSEcCtD
Hydrocodone—Insomnia—Saquinavir—acquired immunodeficiency syndrome	0.0003	0.00122	CcSEcCtD
Hydrocodone—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000299	0.00121	CcSEcCtD
Hydrocodone—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000298	0.00121	CcSEcCtD
Hydrocodone—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000298	0.00121	CcSEcCtD
Hydrocodone—Fatigue—Ritonavir—acquired immunodeficiency syndrome	0.000298	0.00121	CcSEcCtD
Hydrocodone—Asthenia—Indinavir—acquired immunodeficiency syndrome	0.000296	0.0012	CcSEcCtD
Hydrocodone—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000296	0.0012	CcSEcCtD
Hydrocodone—Hypotension—Lamivudine—acquired immunodeficiency syndrome	0.000296	0.0012	CcSEcCtD
Hydrocodone—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.000295	0.0012	CcSEcCtD
Hydrocodone—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000295	0.0012	CcSEcCtD
Hydrocodone—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000295	0.0012	CcSEcCtD
Hydrocodone—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000295	0.0012	CcSEcCtD
Hydrocodone—OPRD1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000295	0.0064	CbGpPWpGaD
Hydrocodone—Dizziness—Zidovudine—acquired immunodeficiency syndrome	0.000294	0.00119	CcSEcCtD
Hydrocodone—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000292	0.00119	CcSEcCtD
Hydrocodone—OPRD1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000289	0.00627	CbGpPWpGaD
Hydrocodone—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000289	0.00117	CcSEcCtD
Hydrocodone—OPRK1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000288	0.00625	CbGpPWpGaD
Hydrocodone—OPRK1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000288	0.00625	CbGpPWpGaD
Hydrocodone—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000287	0.00117	CcSEcCtD
Hydrocodone—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000287	0.00117	CcSEcCtD
Hydrocodone—Insomnia—Lamivudine—acquired immunodeficiency syndrome	0.000287	0.00116	CcSEcCtD
Hydrocodone—Fatigue—Saquinavir—acquired immunodeficiency syndrome	0.000286	0.00116	CcSEcCtD
Hydrocodone—OPRM1—Peptide ligand-binding receptors—CCL3—acquired immunodeficiency syndrome	0.000286	0.00621	CbGpPWpGaD
Hydrocodone—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000285	0.00116	CcSEcCtD
Hydrocodone—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000284	0.00115	CcSEcCtD
Hydrocodone—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.000283	0.00115	CcSEcCtD
Hydrocodone—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.000282	0.00115	CcSEcCtD
Hydrocodone—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.000282	0.00115	CcSEcCtD
Hydrocodone—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.000282	0.00114	CcSEcCtD
Hydrocodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL4—acquired immunodeficiency syndrome	0.000281	0.0061	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.00028	0.00608	CbGpPWpGaD
Hydrocodone—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.00028	0.0219	CbGeAlD
Hydrocodone—Rash—Zidovudine—acquired immunodeficiency syndrome	0.00028	0.00114	CcSEcCtD
Hydrocodone—Asthenia—Efavirenz—acquired immunodeficiency syndrome	0.00028	0.00114	CcSEcCtD
Hydrocodone—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.00028	0.00114	CcSEcCtD
Hydrocodone—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000278	0.00113	CcSEcCtD
Hydrocodone—OPRD1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000277	0.00601	CbGpPWpGaD
Hydrocodone—OPRD1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000277	0.00601	CbGpPWpGaD
Hydrocodone—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000276	0.00112	CcSEcCtD
Hydrocodone—CYP2D6—digestive system—acquired immunodeficiency syndrome	0.000275	0.0215	CbGeAlD
Hydrocodone—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000275	0.00112	CcSEcCtD
Hydrocodone—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000274	0.00111	CcSEcCtD
Hydrocodone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000273	0.00594	CbGpPWpGaD
Hydrocodone—Fatigue—Lamivudine—acquired immunodeficiency syndrome	0.000273	0.00111	CcSEcCtD
Hydrocodone—Dizziness—Indinavir—acquired immunodeficiency syndrome	0.000273	0.00111	CcSEcCtD
Hydrocodone—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.00111	CcSEcCtD
Hydrocodone—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000273	0.00111	CcSEcCtD
Hydrocodone—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.000272	0.0011	CcSEcCtD
Hydrocodone—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.000271	0.0011	CcSEcCtD
Hydrocodone—OPRD1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00027	0.00587	CbGpPWpGaD
Hydrocodone—Asthenia—Delavirdine—acquired immunodeficiency syndrome	0.000268	0.00109	CcSEcCtD
Hydrocodone—CYP3A4—blood—acquired immunodeficiency syndrome	0.000267	0.0208	CbGeAlD
Hydrocodone—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000264	0.00107	CcSEcCtD
Hydrocodone—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000264	0.00107	CcSEcCtD
Hydrocodone—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000263	0.00107	CcSEcCtD
Hydrocodone—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000263	0.00107	CcSEcCtD
Hydrocodone—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000262	0.00107	CcSEcCtD
Hydrocodone—CYP2D6—blood—acquired immunodeficiency syndrome	0.000262	0.0205	CbGeAlD
Hydrocodone—Rash—Indinavir—acquired immunodeficiency syndrome	0.00026	0.00106	CcSEcCtD
Hydrocodone—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00026	0.00106	CcSEcCtD
Hydrocodone—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000259	0.00105	CcSEcCtD
Hydrocodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000259	0.00562	CbGpPWpGaD
Hydrocodone—OPRM1—Peptide ligand-binding receptors—CCR2—acquired immunodeficiency syndrome	0.000259	0.00562	CbGpPWpGaD
Hydrocodone—Headache—Indinavir—acquired immunodeficiency syndrome	0.000259	0.00105	CcSEcCtD
Hydrocodone—OPRK1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000258	0.00561	CbGpPWpGaD
Hydrocodone—Dizziness—Efavirenz—acquired immunodeficiency syndrome	0.000258	0.00105	CcSEcCtD
Hydrocodone—OPRD1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000257	0.00558	CbGpPWpGaD
Hydrocodone—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000254	0.00103	CcSEcCtD
Hydrocodone—OPRK1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000253	0.0055	CbGpPWpGaD
Hydrocodone—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.00102	CcSEcCtD
Hydrocodone—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.00102	CcSEcCtD
Hydrocodone—OPRD1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.00025	0.00542	CbGpPWpGaD
Hydrocodone—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000248	0.00101	CcSEcCtD
Hydrocodone—Asthenia—Ritonavir—acquired immunodeficiency syndrome	0.000248	0.00101	CcSEcCtD
Hydrocodone—Dizziness—Delavirdine—acquired immunodeficiency syndrome	0.000247	0.001	CcSEcCtD
Hydrocodone—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000246	0.000999	CcSEcCtD
Hydrocodone—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000246	0.000999	CcSEcCtD
Hydrocodone—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000245	0.000997	CcSEcCtD
Hydrocodone—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000245	0.000995	CcSEcCtD
Hydrocodone—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000244	0.000993	CcSEcCtD
Hydrocodone—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000244	0.000992	CcSEcCtD
Hydrocodone—OPRM1—Peptide ligand-binding receptors—CXCR4—acquired immunodeficiency syndrome	0.000243	0.00528	CbGpPWpGaD
Hydrocodone—OPRM1—Peptide ligand-binding receptors—CXCL12—acquired immunodeficiency syndrome	0.000243	0.00528	CbGpPWpGaD
Hydrocodone—OPRK1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000243	0.00527	CbGpPWpGaD
Hydrocodone—OPRK1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000243	0.00527	CbGpPWpGaD
Hydrocodone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.00024	0.00521	CbGpPWpGaD
Hydrocodone—Asthenia—Saquinavir—acquired immunodeficiency syndrome	0.000238	0.000969	CcSEcCtD
Hydrocodone—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000237	0.000964	CcSEcCtD
Hydrocodone—OPRK1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000237	0.00515	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR ligand binding—ACKR1—acquired immunodeficiency syndrome	0.000237	0.00514	CbGpPWpGaD
Hydrocodone—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000235	0.000956	CcSEcCtD
Hydrocodone—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000235	0.000955	CcSEcCtD
Hydrocodone—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000235	0.000955	CcSEcCtD
Hydrocodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000234	0.00509	CbGpPWpGaD
Hydrocodone—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000234	0.00095	CcSEcCtD
Hydrocodone—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000233	0.000949	CcSEcCtD
Hydrocodone—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000232	0.000942	CcSEcCtD
Hydrocodone—Dizziness—Ritonavir—acquired immunodeficiency syndrome	0.000228	0.000927	CcSEcCtD
Hydrocodone—Asthenia—Lamivudine—acquired immunodeficiency syndrome	0.000227	0.000924	CcSEcCtD
Hydrocodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000227	0.00493	CbGpPWpGaD
Hydrocodone—OPRK1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000225	0.00489	CbGpPWpGaD
Hydrocodone—OPRD1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000225	0.00489	CbGpPWpGaD
Hydrocodone—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000224	0.000911	CcSEcCtD
Hydrocodone—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000222	0.000901	CcSEcCtD
Hydrocodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.00022	0.00478	CbGpPWpGaD
Hydrocodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.00022	0.00478	CbGpPWpGaD
Hydrocodone—Dizziness—Saquinavir—acquired immunodeficiency syndrome	0.00022	0.000893	CcSEcCtD
Hydrocodone—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000219	0.000892	CcSEcCtD
Hydrocodone—OPRK1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000219	0.00476	CbGpPWpGaD
Hydrocodone—OPRM1—G alpha (i) signalling events—CCR2—acquired immunodeficiency syndrome	0.000218	0.00474	CbGpPWpGaD
Hydrocodone—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000218	0.000884	CcSEcCtD
Hydrocodone—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.000217	0.000884	CcSEcCtD
Hydrocodone—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000216	0.0169	CbGeAlD
Hydrocodone—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000216	0.000879	CcSEcCtD
Hydrocodone—OPRM1—GPCR ligand binding—CCL4—acquired immunodeficiency syndrome	0.000214	0.00465	CbGpPWpGaD
Hydrocodone—CYP2D6—nervous system—acquired immunodeficiency syndrome	0.000213	0.0166	CbGeAlD
Hydrocodone—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000211	0.000858	CcSEcCtD
Hydrocodone—OPRD1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000211	0.00458	CbGpPWpGaD
Hydrocodone—Dizziness—Lamivudine—acquired immunodeficiency syndrome	0.00021	0.000852	CcSEcCtD
Hydrocodone—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000209	0.000851	CcSEcCtD
Hydrocodone—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000209	0.00085	CcSEcCtD
Hydrocodone—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000208	0.0163	CbGeAlD
Hydrocodone—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000208	0.000846	CcSEcCtD
Hydrocodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000205	0.00446	CbGpPWpGaD
Hydrocodone—OPRM1—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000205	0.00446	CbGpPWpGaD
Hydrocodone—OPRM1—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000205	0.00446	CbGpPWpGaD
Hydrocodone—CYP2D6—central nervous system—acquired immunodeficiency syndrome	0.000205	0.016	CbGeAlD
Hydrocodone—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000205	0.000833	CcSEcCtD
Hydrocodone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000203	0.0044	CbGpPWpGaD
Hydrocodone—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000201	0.000819	CcSEcCtD
Hydrocodone—OPRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.0002	0.00435	CbGpPWpGaD
Hydrocodone—Rash—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.000812	CcSEcCtD
Hydrocodone—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.000811	CcSEcCtD
Hydrocodone—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000199	0.000807	CcSEcCtD
Hydrocodone—OPRK1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000197	0.00428	CbGpPWpGaD
Hydrocodone—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000197	0.000802	CcSEcCtD
Hydrocodone—OPRD1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000197	0.00428	CbGpPWpGaD
Hydrocodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000193	0.00419	CbGpPWpGaD
Hydrocodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000193	0.00419	CbGpPWpGaD
Hydrocodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000192	0.00417	CbGpPWpGaD
Hydrocodone—OPRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.00019	0.00414	CbGpPWpGaD
Hydrocodone—OPRM1—TCR Signaling Pathway—CD4—acquired immunodeficiency syndrome	0.00019	0.00413	CbGpPWpGaD
Hydrocodone—OPRD1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00019	0.00412	CbGpPWpGaD
Hydrocodone—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000188	0.000765	CcSEcCtD
Hydrocodone—OPRM1—Peptide ligand-binding receptors—CCL5—acquired immunodeficiency syndrome	0.000185	0.00402	CbGpPWpGaD
Hydrocodone—OPRK1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000185	0.00401	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000178	0.00387	CbGpPWpGaD
Hydrocodone—OPRD1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000176	0.00383	CbGpPWpGaD
Hydrocodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000174	0.00377	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000173	0.00376	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000168	0.00364	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000168	0.00364	CbGpPWpGaD
Hydrocodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000168	0.00364	CbGpPWpGaD
Hydrocodone—OPRM1—Peptide ligand-binding receptors—CCR5—acquired immunodeficiency syndrome	0.000167	0.00362	CbGpPWpGaD
Hydrocodone—OPRK1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000166	0.00361	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000164	0.00356	CbGpPWpGaD
Hydrocodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000163	0.00354	CbGpPWpGaD
Hydrocodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000163	0.00354	CbGpPWpGaD
Hydrocodone—CYP2D6—brain—acquired immunodeficiency syndrome	0.000163	0.0127	CbGeAlD
Hydrocodone—OPRD1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00016	0.00347	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000156	0.0034	CbGpPWpGaD
Hydrocodone—OPRM1—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000156	0.00339	CbGpPWpGaD
Hydrocodone—OPRK1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000154	0.00335	CbGpPWpGaD
Hydrocodone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000151	0.00328	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000148	0.00322	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000147	0.00319	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000147	0.00319	CbGpPWpGaD
Hydrocodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000147	0.00319	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000146	0.00317	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000144	0.00312	CbGpPWpGaD
Hydrocodone—OPRM1—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.000141	0.00306	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00014	0.00304	CbGpPWpGaD
Hydrocodone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000132	0.00287	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000132	0.00287	CbGpPWpGaD
Hydrocodone—OPRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000131	0.00284	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00013	0.00282	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000128	0.00277	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000124	0.0027	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000124	0.0027	CbGpPWpGaD
Hydrocodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000124	0.0027	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000121	0.00264	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000118	0.00257	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000115	0.0025	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000112	0.00243	CbGpPWpGaD
Hydrocodone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000112	0.00243	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.00011	0.00238	CbGpPWpGaD
Hydrocodone—OPRM1—TCR Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000103	0.00224	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000101	0.0022	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000101	0.00219	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000101	0.00219	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	9.68e-05	0.0021	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	9.68e-05	0.0021	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	9.48e-05	0.00206	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	9.48e-05	0.00206	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	9.46e-05	0.00205	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	9.15e-05	0.00199	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	8.88e-05	0.00193	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	8.84e-05	0.00192	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8.75e-05	0.0019	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	8.61e-05	0.00187	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	8.61e-05	0.00187	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	8.52e-05	0.00185	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.49e-05	0.00184	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.49e-05	0.00184	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	8.31e-05	0.0018	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	8.31e-05	0.0018	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	8.03e-05	0.00174	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	7.67e-05	0.00167	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	7.55e-05	0.00164	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	7.55e-05	0.00164	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	7.5e-05	0.00163	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	7.47e-05	0.00162	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	7.21e-05	0.00157	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	7.17e-05	0.00156	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	7.17e-05	0.00156	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	7.1e-05	0.00154	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	7.02e-05	0.00153	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	7.02e-05	0.00153	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	6.78e-05	0.00147	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	6.55e-05	0.00142	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	6.5e-05	0.00141	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	6.49e-05	0.00141	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	6.45e-05	0.0014	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	6.38e-05	0.00139	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	6.38e-05	0.00139	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	6.32e-05	0.00137	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	6.23e-05	0.00135	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.98e-05	0.0013	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.9e-05	0.00128	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	5.74e-05	0.00125	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	5.7e-05	0.00124	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	5.66e-05	0.00123	CbGpPWpGaD
Hydrocodone—CYP2D6—Metabolism—TAT—acquired immunodeficiency syndrome	5.58e-05	0.00121	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	5.41e-05	0.00117	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	5.34e-05	0.00116	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	5.26e-05	0.00114	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.24e-05	0.00114	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	5.17e-05	0.00112	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	5.08e-05	0.0011	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	5.08e-05	0.0011	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	4.85e-05	0.00105	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	4.81e-05	0.00105	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	4.78e-05	0.00104	CbGpPWpGaD
Hydrocodone—CYP2D6—Metabolism—AGPS—acquired immunodeficiency syndrome	4.74e-05	0.00103	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.74e-05	0.00103	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.46e-05	0.000968	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.46e-05	0.000968	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	4.43e-05	0.000962	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	4.37e-05	0.000949	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.01e-05	0.00087	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.87e-05	0.00084	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.81e-05	0.000827	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	3.77e-05	0.000818	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	3.77e-05	0.000818	CbGpPWpGaD
Hydrocodone—OPRD1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.75e-05	0.000815	CbGpPWpGaD
Hydrocodone—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	3.65e-05	0.000792	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.48e-05	0.000757	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	3.41e-05	0.00074	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.39e-05	0.000736	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.34e-05	0.000725	CbGpPWpGaD
Hydrocodone—OPRK1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	3.29e-05	0.000715	CbGpPWpGaD
Hydrocodone—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.1e-05	0.000673	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.06e-05	0.000664	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.99e-05	0.000649	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	2.87e-05	0.000622	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	2.82e-05	0.000613	CbGpPWpGaD
Hydrocodone—OPRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	2.78e-05	0.000604	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	2.58e-05	0.000561	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	2.53e-05	0.000548	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	2.01e-05	0.000437	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	2e-05	0.000435	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.77e-05	0.000383	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.76e-05	0.000381	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.49e-05	0.000324	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	1.48e-05	0.000322	CbGpPWpGaD
Hydrocodone—OPRD1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.18e-05	0.000257	CbGpPWpGaD
Hydrocodone—OPRK1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.04e-05	0.000225	CbGpPWpGaD
Hydrocodone—CYP2D6—Metabolism—ALB—acquired immunodeficiency syndrome	9.73e-06	0.000211	CbGpPWpGaD
Hydrocodone—OPRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	8.77e-06	0.00019	CbGpPWpGaD
Hydrocodone—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	6.36e-06	0.000138	CbGpPWpGaD
